TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04217954
Drug: OXA, 5-FU and bevacizumab plus Toripalimab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks.
Study: NCT01370031
Drug: Clenil® Modulite® via AeroChamber Plus™
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
Study: NCT01370031
Drug: Clenil® Modulite® via AeroChamber Plus™ plus charcoal block
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
Study: NCT01470144
Drug: Epoprostenol
Normalized name: Epoprostenol
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
Study: NCT02157324
Drug: acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00842192
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
Study: NCT00756509
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg/d orally
Study: NCT00006038
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006038
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006038
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00473590
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg administered by intravenous infusion
Study: NCT00473590
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m\^2 administered by intravenous bolus injection
Study: NCT02153983
Drug: Colchicine 0.6Mg Cap
Normalized name: COLCHICINE 0.6MG CAP
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6 mg given twice daily
Study: NCT02153983
Drug: Colchicine 0.6Mg Tab
Normalized name: COLCHICINE 0.6MG TAB
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label colchicine
Study: NCT01034020
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04685512
Drug: tenofovir disoproxil and emtricitabine
Normalized name: tenofovir disoproxil and emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental drugs administration of 7-day short course TDF/FTC
Study: NCT00295997
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00295997
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00295997
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00295997
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02404805
Drug: dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dolutegravir tablets 50mg, once daily x 7 days.
Study: NCT02404805
Drug: simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir tablets 150mg, once daily x 7 days.
Study: NCT01625091
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
Study: NCT00779831
Drug: 120 mg Pseudoephedrine hydrochloride extended release tablets
Normalized name: pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00445146
Drug: EVG
Normalized name: EVG
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elvitegravir (EVG) tablet administered orally once daily with food
Study: NCT01256879
Drug: Drug: cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
Study: NCT02644915
Drug: Edaravone
Normalized name: Edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
Study: NCT00003405
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003405
Drug: bromodeoxyuridine
Normalized name: Bromodeoxyuridine
DrugBank: Broxuridine (DB12028)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003405
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003405
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003405
Drug: idoxuridine
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003405
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003405
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01654692
Drug: Ipilimumab and Fotemustine
Normalized name: Ipilimumab
DrugBank: Fotemustine (DB04106)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
Study: NCT00619723
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
Study: NCT01184495
Drug: Epoetin Alfa-BioManguinhos
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous administration of EPO-BioManguinhos
Study: NCT01184495
Drug: Epoetin Alfa-BioSimilar
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous administration of EPO-BioSimilar
Study: NCT01313377
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01313377
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03644186
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy plus HER2 Blockade
Study: NCT02390947
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg p.o. qd
Study: NCT01541085
Drug: Darunavir/Ritonavir (DRV/r)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
Study: NCT01541085
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
Study: NCT04678050
Drug: Ketamine/ propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
Study: NCT04678050
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
Study: NCT05099250
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetic agent
Study: NCT05099250
Drug: magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
Study: NCT02666443
Drug: Control intervention (no dexamethasone)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
Study: NCT02666443
Drug: Peri-neural Dexamethasone 1 mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
Study: NCT02666443
Drug: Intravenous Dexamethasone 1 mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
Study: NCT03644186
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy plus HER2 Blockade
Study: NCT03644186
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy plus HER2 Blockade
Study: NCT03644186
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT03644186
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT03644186
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT03644186
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT03853109
Drug: AMG 404
Normalized name: Anti-pd-1 monoclonal antibody amg 404
DrugBank: AMG 424 (DB17357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
Study: NCT04310995
Drug: Nicorandil 5mg tid
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
Study: NCT04310995
Drug: Diltiazem 180mg qd
Normalized name: diltiazem hydrochloride 180 MG
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
Study: NCT04310995
Drug: Isosorbide Mononitrate 50mg qd
Normalized name: isosorbide mononitrate 50 MG
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
Study: NCT04512521
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab therapy
Study: NCT03888066
Drug: Patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Study: NCT03857646
Drug: Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid
Normalized name: Medium-Chain Triglycerides
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
Study: NCT00168935
Drug: Fresubin protein energy Drink (CAVE! nutritional intervention)
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01860235
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: % eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
Study: NCT01435083
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 µg, oral lyophilisate, sublingual use
Study: NCT01722968
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
Study: NCT01722968
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2 iv weekly
Study: NCT04518878
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed dose of eltrombopag oral 25mg daily
Study: NCT04518878
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Study: NCT00030719
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00030719
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00030719
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00030719
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030719
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00030719
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03422874
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
Study: NCT00456638
Drug: Depodur
Normalized name: Depodur
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depodur vs. traditional management
Study: NCT01386528
Drug: nonacog beta pegol
Normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
Study: NCT01559298
Drug: Aspirin (80 mg/d) + clopidogrel (75 mg/d)
Normalized name: D
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
Study: NCT01559298
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study: NCT00785655
Drug: Dermacyd PH_DETINLYN (Lactic Acid)
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03516448
Drug: Tyroserleutide for injection
Normalized name: Tyroserleutide
DrugBank: Tyroserleutide (DB17300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg/d, 5days,ivgtt
Study: NCT02856555
Drug: Firsocostat
Normalized name: Firsocostat
DrugBank: Firsocostat (DB16166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules orally once daily.
Study: NCT02340481
Drug: Loperamide hydrochloride + simethicone chewable tablet
Normalized name: loperamide hydrochloride / simethicone Chewable Tablet
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
Study: NCT02340481
Drug: Loperamide hydrochloride
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each capsule contains 2 mg of loperamide hydrochloride
Study: NCT02340481
Drug: Loperamide hydrochloride + simethicone chewable placebo tablet
Normalized name: loperamide hydrochloride / simethicone Chewable Tablet
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
Study: NCT02340481
Drug: Loperamide hydrochloride placebo capsule
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo matched to loperamide hydrochloride capsule.
Study: NCT00005603
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005603
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005603
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005603
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005603
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005603
Drug: thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005603
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03196843
Drug: Raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
Study: NCT01391715
Drug: rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rabeprazole 20mg bid per day for 2 weeks
Study: NCT01391715
Drug: standard dose rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rabeprazole 20mg qd per day for 2 weeks
Study: NCT01437488
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator
Study: NCT01437488
Drug: Neulasta
Normalized name: Neulasta
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
Study: NCT00573261
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Study: NCT02872428
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By infusion over 1 hour
Study: NCT02187991
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
Study: NCT02187991
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle